PNV Stock Overview
Designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.31 |
| 52 Week High | AU$2.78 |
| 52 Week Low | AU$0.93 |
| Beta | 1.58 |
| 1 Month Change | 11.54% |
| 3 Month Change | -26.89% |
| 1 Year Change | -37.26% |
| 3 Year Change | 6.53% |
| 5 Year Change | -52.55% |
| Change since IPO | 552.50% |
Recent News & Updates
PolyNovo Limited's (ASX:PNV) 25% Jump Shows Its Popularity With Investors
May 22
Is There Now An Opportunity In PolyNovo Limited (ASX:PNV)?
May 08
NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects
Launch of NovoSorb MTX in the U.S. and geographic expansion could drive revenue growth and diversify revenue sources.PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 03PolyNovo Limited's (ASX:PNV) Share Price Is Still Matching Investor Opinion Despite 37% Slump
Feb 26Recent updates
PolyNovo Limited's (ASX:PNV) 25% Jump Shows Its Popularity With Investors
May 22Is There Now An Opportunity In PolyNovo Limited (ASX:PNV)?
May 08NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects
Launch of NovoSorb MTX in the U.S. and geographic expansion could drive revenue growth and diversify revenue sources.PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 03PolyNovo Limited's (ASX:PNV) Share Price Is Still Matching Investor Opinion Despite 37% Slump
Feb 26An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 39% Undervalued
Feb 11Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?
Oct 10PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital
Aug 28PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
Aug 06PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
May 08When Should You Buy PolyNovo Limited (ASX:PNV)?
Feb 28Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S
Feb 02PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 08Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?
Sep 22When Should You Buy PolyNovo Limited (ASX:PNV)?
Jun 26Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?
May 30Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price
Apr 18Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?
Mar 23Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?
Feb 05Returns At PolyNovo (ASX:PNV) Are On The Way Up
Nov 16PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price
Nov 01What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?
Jul 29PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital
Jun 15Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)
May 16We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt
Apr 28There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital
Mar 07Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?
Dec 13PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why
Oct 19Shareholder Returns
| PNV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -12.4% | -1.3% | 0.1% |
| 1Y | -37.3% | -11.0% | 6.2% |
Return vs Industry: PNV underperformed the Australian Medical Equipment industry which returned -11% over the past year.
Return vs Market: PNV underperformed the Australian Market which returned 6.2% over the past year.
Price Volatility
| PNV volatility | |
|---|---|
| PNV Average Weekly Movement | 11.7% |
| Medical Equipment Industry Average Movement | 12.1% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 17.1% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: PNV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PNV's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 282 | Robyn Elliott | polynovo.com |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
PolyNovo Limited Fundamentals Summary
| PNV fundamental statistics | |
|---|---|
| Market cap | AU$901.55m |
| Earnings (TTM) | AU$5.91m |
| Revenue (TTM) | AU$115.58m |
Is PNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNV income statement (TTM) | |
|---|---|
| Revenue | AU$115.58m |
| Cost of Revenue | AU$15.72m |
| Gross Profit | AU$99.86m |
| Other Expenses | AU$93.95m |
| Earnings | AU$5.91m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0085 |
| Gross Margin | 86.40% |
| Net Profit Margin | 5.11% |
| Debt/Equity Ratio | 4.5% |
How did PNV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 22:35 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PolyNovo Limited is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Andrew Paine | CLSA |